BACKGROUND: CXCL12 (SDF-1alpha) is a chemokine, which plays an important role in normal B-cell lymphopoesis, migration and homing to the bone marrow (BM) and previous studies have suggested a role for CXCL12 and its receptor CXCR4 in the pathogenesis of ALL. PURPOSE: CXCL12 levels in serum were evaluated from ALL-children and controls. The biological effect of recombinant CXCL12 on primary leukaemic cells was investigated. Signalling via the CXCL12/CXCR4 axis was further characterized in an in vitro model using the pre-B leukaemic cell line Nalm-6. RESULTS: The serum level of CXCL12 in children at diagnosis of pre-B-ALL is significantly higher than in healthy children (4.8 (0-32) ng/ml vs. 0 (0-3.2) ng/ml, P < 0.001). After completed chemotherapy, CXCL12 decreases to levels comparable to those found in the control group. In addition, we found that recombinant CXCL12 enhances pre-B leukaemic cell proliferation in vitro. The CXCL12/CXCR4 axis is able to initiate functional signalling and we show that STAT5 is activated in CD19+ leukaemic cells from BM of ALL patients and in the leukaemic cell line Nalm-6. CONCLUSION: Our findings suggest that CXCL12 may have a role in leukaemic cell proliferation and survival during childhood ALL. (c) 2008 Wiley-Liss, Inc.
BACKGROUND:CXCL12 (SDF-1alpha) is a chemokine, which plays an important role in normal B-cell lymphopoesis, migration and homing to the bone marrow (BM) and previous studies have suggested a role for CXCL12 and its receptor CXCR4 in the pathogenesis of ALL. PURPOSE:CXCL12 levels in serum were evaluated from ALL-children and controls. The biological effect of recombinant CXCL12 on primary leukaemic cells was investigated. Signalling via the CXCL12/CXCR4 axis was further characterized in an in vitro model using the pre-B leukaemic cell line Nalm-6. RESULTS: The serum level of CXCL12 in children at diagnosis of pre-B-ALL is significantly higher than in healthy children (4.8 (0-32) ng/ml vs. 0 (0-3.2) ng/ml, P < 0.001). After completed chemotherapy, CXCL12 decreases to levels comparable to those found in the control group. In addition, we found that recombinant CXCL12 enhances pre-B leukaemic cell proliferation in vitro. The CXCL12/CXCR4 axis is able to initiate functional signalling and we show that STAT5 is activated in CD19+ leukaemic cells from BM of ALL patients and in the leukaemic cell line Nalm-6. CONCLUSION: Our findings suggest that CXCL12 may have a role in leukaemic cell proliferation and survival during childhood ALL. (c) 2008 Wiley-Liss, Inc.
Authors: Aparecida de Lourdes Perim; Marla Karine Amarante; Roberta Losi Guembarovski; Carlos Eduardo Coral de Oliveira; Maria Angelica Ehara Watanabe Journal: Cell Mol Life Sci Date: 2015-01-09 Impact factor: 9.261
Authors: Jelena Põlajeva; Tobias Bergström; Per-Henrik Edqvist; Anders Lundequist; Anna Sjösten; Gunnar Nilsson; Anja Smits; Michael Bergqvist; Fredrik Pontén; Bengt Westermark; Gunnar Pejler; Karin Forsberg Nilsson; Elena Tchougounova Journal: Mol Oncol Date: 2013-09-18 Impact factor: 6.603
Authors: Daniel E Frigo; Andrea B Sherk; Bryan M Wittmann; John D Norris; Qianben Wang; James D Joseph; Aidan P Toner; Myles Brown; Donald P McDonnell Journal: Mol Endocrinol Date: 2009-05-21
Authors: Anna Mikosik; Izabella Henc; Katarzyna Ruckemann-Dziurdzińska; Joanna E Frąckowiak; Anna Płoszyńska; Anna Balcerska; Ewa Bryl; Jacek M Witkowski Journal: PLoS One Date: 2015-08-28 Impact factor: 3.240
Authors: Juan Carlos Balandrán; Jessica Purizaca; Jennifer Enciso; David Dozal; Antonio Sandoval; Elva Jiménez-Hernández; Leticia Alemán-Lazarini; Vadim Perez-Koldenkova; Henry Quintela-Núñez Del Prado; Jussara Rios de Los Ríos; Héctor Mayani; Vianney Ortiz-Navarrete; Monica L Guzman; Rosana Pelayo Journal: Front Immunol Date: 2017-01-05 Impact factor: 7.561